Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. [electronic resource]
Producer: 20050817Description: 741-70 p. digitalISSN:- 1535-3532
- Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use
- Celecoxib
- Chromans -- therapeutic use
- Clinical Trials as Topic
- Cyclooxygenase Inhibitors -- therapeutic use
- Drug Industry -- legislation & jurisprudence
- Drug and Narcotic Control -- legislation & jurisprudence
- Humans
- Hypoglycemic Agents -- therapeutic use
- Isoxazoles -- therapeutic use
- Lactones -- therapeutic use
- Myocardial Infarction -- chemically induced
- Paternalism
- Platelet Aggregation Inhibitors -- therapeutic use
- Pyrazoles -- therapeutic use
- Sulfonamides -- therapeutic use
- Sulfones -- therapeutic use
- Thiazolidinediones -- therapeutic use
- Troglitazone
- Truth Disclosure
- United States
- United States Food and Drug Administration -- legislation & jurisprudence
- Vasodilator Agents -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.